Demand here is measured, not guessed: every one of 1,773 keywords carries an 87-month (2019–2026) monthly series built by co-measuring Google Trends against Google Ads volumes. The trajectories below are real month-to-month variation.
The race
| Molecule | UK searches / month | Keywords | The read |
|---|---|---|---|
| Mounjaro (tirzepatide) | 1,870,000 | 509 | The runaway leader — bigger than any generic cluster |
| Wegovy (semaglutide) | 370,000 | 243 | The licensed pioneer, now a clear #2 |
| Ozempic | 234,000 | 149 | Famous, unlicensed for weight loss in the UK, still heavily searched |
| Tirzepatide (API name) | 93,000 | 28 | Clinical-register demand |
| Retatrutide | 90,000 | 11 | Pre-launch surge — the next wave arriving early |
| Semaglutide (API name) | 67,000 | 39 | |
| Orlistat | 13,000 | 22 | The old oral standby |
| Saxenda | 2,100 | 4 | Collapapsed post-Wegovy — a finding, not a gap |
Two structural notes. First, the entrants tell their own story on a time axis: Mounjaro's line begins in 2022 and crosses everything within 18 months. Second, smallness is signal — Saxenda's four keywords are the finding: the market has moved on.
Who owns the search language
Of the 8.5M monthly total: generic 5.2M (62%) · molecule 2.8M (33%) · retailer-brand 0.5M (6%). The generic pool is the demand still up for grabs; the molecule pool is the differentiation battleground — and it is the growth class. Any content strategy that organises by generic topic alone is fighting yesterday's war: the category increasingly speaks in product names.
Where the funnel is fat
| Journey stage | Monthly demand | Example real searches |
|---|---|---|
| Treatment research | ~2.8M | "wegovy vs mounjaro", "how does mounjaro work" |
| Eligibility | ~1.8M | "am i eligible for wegovy", "bmi for mounjaro" |
| Provider selection | ~1.9M | "asda pharmacy mounjaro price", "best online pharmacy mounjaro" |
| Usage & management | ~50K | "mounjaro dosing schedule", "missed dose wegovy" |
| Purchase (transactional) | <2K | "buy mounjaro online uk" |
The purchase layer is almost non-existent: this market converts through research content, not checkout terms. Whoever owns the research answers owns the patient.
→ Next: who actually captures that demand — and how AI answers re-rank it